Leap Therapeutics Inc LPTX.OQ LPTX.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Leap Therapeutics Inc is for a loss of 38 cents per share.
The one available analyst rating on the shares is "hold".
The mean earnings estimate of analysts had risen by about 6.1% in the last three months.
This summary was machine generated May 9 at 15:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.